TScan Therapeutics, Inc. TCRX
TScan Therapeutics, Inc. (Nasdaq: TCRX) is an oncology drug developer. Its lead program, TSC-101, is in Phase 3 for AML and MDS patients undergoing allogeneic HCT (prevention of relapse; HLA-A*02:01).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| TSC-101 (ALLOHA-2, Phase 3 registrational; first patient dosed July 2026) | AML/MDS post-allogeneic HCT | cell therapy | Phase 3 |
| TSC-101 (ALLOHA Phase 1, ongoing Cohort C) | Heme malignancies post-allogeneic HCT | cell therapy | Phase 1 |
| TSC-102-A01 / TSC-102-A03 | Heme malignancies post-HCT (HLA A*01:01 and A*03:01; CD45 epitopes) | cell therapy | Pre-clinical |
| Multiplex TCR-T / in vivo engineered TCR-T (PLEXI-T Phase 1 enrollment paused) | Solid tumors | cell therapy | Pre-clinical |
| Autoimmune target discovery (with Amgen on Crohn's disease) | Ankylosing spondylitis, ulcerative colitis, scleroderma, Crohn's | cell therapy | Pre-clinical |
Recent results and decisions
- Aug 12, 2026started First patient dosed in July 2026 in the Phase 3 ALLOHA-2 pivotal trial of TSC-101.
In July, the Company announced that it has dosed the first patient in the ongoing Phase 3
Filing - Aug 12, 2026positive Cohort C: 79% (11/14) achieved complete donor chimerism within about three weeks of first TSC-101 infusion; about 90% manufacturing success (17/19).
79% of patients (11/14) achieved complete donor chimerism within ~three weeks of receiving their first infusion of TSC-101
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.